Epidemiologic  ||| S:0 E:14 ||| JJ
characteristics ||| S:14 E:29 ||| NNS
,  ||| S:29 E:31 ||| ,
serotypes ||| S:31 E:40 ||| NN
,  ||| S:40 E:42 ||| ,
and  ||| S:42 E:46 ||| CC
antimicrobial  ||| S:46 E:60 ||| JJ
susceptibilities  ||| S:60 E:77 ||| NN
of  ||| S:77 E:80 ||| IN
invasive  ||| S:80 E:89 ||| FW
Streptococcus  ||| S:89 E:103 ||| FW
pneumoniae  ||| S:103 E:114 ||| FW
isolates  ||| S:114 E:123 ||| FW
in  ||| S:123 E:126 ||| IN
a  ||| S:126 E:128 ||| DT
nationwide  ||| S:128 E:139 ||| JJ
surveillance  ||| S:139 E:152 ||| NN
study  ||| S:152 E:158 ||| NN
in  ||| S:158 E:161 ||| IN
Lebanon  ||| S:161 E:169 ||| NNP
Invasive  ||| S:169 E:178 ||| NNP
pneumococcal  ||| S:178 E:191 ||| JJ
disease  ||| S:191 E:199 ||| NN
( ||| S:199 E:200 ||| -LRB-
IPD ||| S:200 E:203 ||| NNP
)  ||| S:203 E:205 ||| -RRB-
associated  ||| S:205 E:216 ||| VBN
with  ||| S:216 E:221 ||| IN
Streptococcus  ||| S:221 E:235 ||| NNP
pneumonia  ||| S:235 E:245 ||| NN
is  ||| S:245 E:248 ||| VBZ
a  ||| S:248 E:250 ||| DT
major  ||| S:250 E:256 ||| JJ
public  ||| S:256 E:263 ||| JJ
health  ||| S:263 E:270 ||| NN
problem  ||| S:270 E:278 ||| NN
worldwide  ||| S:278 E:288 ||| NN
for  ||| S:288 E:292 ||| IN
all  ||| S:292 E:296 ||| DT
age  ||| S:296 E:300 ||| NN
groups ||| S:300 E:306 ||| NNS
,  ||| S:306 E:308 ||| ,
including  ||| S:308 E:318 ||| VBG
in  ||| S:318 E:321 ||| IN
Lebanon ||| S:321 E:328 ||| NNP
.  ||| S:328 E:330 ||| .
Prevention  ||| S:330 E:341 ||| NN
through  ||| S:341 E:349 ||| IN
vaccination  ||| S:349 E:361 ||| NN
remains  ||| S:361 E:369 ||| VBZ
the  ||| S:369 E:373 ||| DT
most  ||| S:373 E:378 ||| RBS
valuable  ||| S:378 E:387 ||| JJ
tool  ||| S:387 E:392 ||| NN
to  ||| S:392 E:395 ||| TO
decrease  ||| S:395 E:404 ||| VB
the  ||| S:404 E:408 ||| DT
burden  ||| S:408 E:415 ||| NN
of  ||| S:415 E:418 ||| IN
disease ||| S:418 E:425 ||| NN
.  ||| S:425 E:427 ||| .
Pneumococcal  ||| S:427 E:440 ||| JJ
conjugate  ||| S:440 E:450 ||| JJ
vaccine  ||| S:450 E:458 ||| NN
7  ||| S:458 E:460 ||| CD
( ||| S:460 E:461 ||| -LRB-
PCV7 ||| S:461 E:465 ||| NNP
) ||| S:465 E:466 ||| -RRB-
,  ||| S:466 E:468 ||| ,
marketed  ||| S:468 E:477 ||| VBD
internationally  ||| S:477 E:493 ||| RB
including  ||| S:493 E:503 ||| VBG
in  ||| S:503 E:506 ||| IN
the  ||| S:506 E:510 ||| DT
Middle  ||| S:510 E:517 ||| NNP
East  ||| S:517 E:522 ||| NNP
and  ||| S:522 E:526 ||| CC
North  ||| S:526 E:532 ||| NNP
Africa  ||| S:532 E:539 ||| NNP
region  ||| S:539 E:546 ||| NN
for  ||| S:546 E:550 ||| IN
the  ||| S:550 E:554 ||| DT
prevention  ||| S:554 E:565 ||| NN
of  ||| S:565 E:568 ||| IN
IPD ||| S:568 E:571 ||| NNP
,  ||| S:571 E:573 ||| ,
was  ||| S:573 E:577 ||| VBD
introduced  ||| S:577 E:588 ||| VBN
in  ||| S:588 E:591 ||| IN
Lebanon  ||| S:591 E:599 ||| NNP
in  ||| S:599 E:602 ||| IN
2006 ||| S:602 E:606 ||| CD
,  ||| S:606 E:608 ||| ,
followed  ||| S:608 E:617 ||| VBN
by  ||| S:617 E:620 ||| IN
PCV10  ||| S:620 E:626 ||| NNP
and  ||| S:626 E:630 ||| CC
PCV13  ||| S:630 E:636 ||| CD
in  ||| S:636 E:639 ||| IN
2010 ||| S:639 E:643 ||| CD
.  ||| S:643 E:645 ||| .
However ||| S:645 E:652 ||| RB
,  ||| S:652 E:654 ||| ,
none  ||| S:654 E:659 ||| NN
of  ||| S:659 E:662 ||| IN
these  ||| S:662 E:668 ||| DT
is  ||| S:668 E:671 ||| VBZ
currently  ||| S:671 E:681 ||| RB
part  ||| S:681 E:686 ||| NN
of  ||| S:686 E:689 ||| IN
the  ||| S:689 E:693 ||| DT
Extended  ||| S:693 E:702 ||| JJ
Program  ||| S:702 E:710 ||| NN
of  ||| S:710 E:713 ||| IN
Immunization  ||| S:713 E:726 ||| NNP
schedule  ||| S:726 E:735 ||| NN
and  ||| S:735 E:739 ||| CC
published  ||| S:739 E:749 ||| VBN
data  ||| S:749 E:754 ||| NNS
on  ||| S:754 E:757 ||| IN
IPD  ||| S:757 E:761 ||| NNP
incidence ||| S:761 E:770 ||| NN
,  ||| S:770 E:772 ||| ,
pneumococcal  ||| S:772 E:785 ||| JJ
serotypes  ||| S:785 E:795 ||| NN
and  ||| S:795 E:799 ||| CC
vaccine  ||| S:799 E:807 ||| NN
coverage  ||| S:807 E:816 ||| NN
in  ||| S:816 E:819 ||| IN
the  ||| S:819 E:823 ||| DT
region  ||| S:823 E:830 ||| NN
are  ||| S:830 E:834 ||| VBP
lacking ||| S:834 E:841 ||| VBG
.  ||| S:841 E:843 ||| .
The  ||| S:843 E:847 ||| DT
Lebanese  ||| S:847 E:856 ||| JJ
Inter-Hospital  ||| S:856 E:871 ||| JJ
Pneumococcal  ||| S:871 E:884 ||| NNP
Surveillance  ||| S:884 E:897 ||| NNP
Program  ||| S:897 E:905 ||| NNP
is  ||| S:905 E:908 ||| VBZ
a  ||| S:908 E:910 ||| DT
surveillance  ||| S:910 E:923 ||| NN
system  ||| S:923 E:930 ||| NN
set  ||| S:930 E:934 ||| VBN
up  ||| S:934 E:937 ||| RP
to  ||| S:937 E:940 ||| TO
determine  ||| S:940 E:950 ||| VB
the  ||| S:950 E:954 ||| DT
burden  ||| S:954 E:961 ||| NN
of  ||| S:961 E:964 ||| IN
IPD  ||| S:964 E:968 ||| NNP
and  ||| S:968 E:972 ||| CC
the  ||| S:972 E:976 ||| DT
prevalent  ||| S:976 E:986 ||| JJ
serotypes  ||| S:986 E:996 ||| JJ
responsible ||| S:996 E:1007 ||| JJ
.  ||| S:1007 E:1009 ||| .
The  ||| S:1009 E:1013 ||| DT
aim  ||| S:1013 E:1017 ||| NN
of  ||| S:1017 E:1020 ||| IN
this  ||| S:1020 E:1025 ||| DT
prospective  ||| S:1025 E:1037 ||| JJ
6-year  ||| S:1037 E:1044 ||| CD
study  ||| S:1044 E:1050 ||| NN
carried  ||| S:1050 E:1058 ||| VBD
out  ||| S:1058 E:1062 ||| RP
in  ||| S:1062 E:1065 ||| IN
78  ||| S:1065 E:1068 ||| CD
hospitals  ||| S:1068 E:1078 ||| NNS
throughout  ||| S:1078 E:1089 ||| IN
Lebanon  ||| S:1089 E:1097 ||| NNP
was  ||| S:1097 E:1101 ||| VBD
to  ||| S:1101 E:1104 ||| TO
obtain  ||| S:1104 E:1111 ||| VB
such  ||| S:1111 E:1116 ||| JJ
data  ||| S:1116 E:1121 ||| NNS
to  ||| S:1121 E:1124 ||| TO
help  ||| S:1124 E:1129 ||| VB
health  ||| S:1129 E:1136 ||| NN
authorities  ||| S:1136 E:1148 ||| NNS
make  ||| S:1148 E:1153 ||| VBP
informed  ||| S:1153 E:1162 ||| VBN
decisions  ||| S:1162 E:1172 ||| NNS
on  ||| S:1172 E:1175 ||| IN
the  ||| S:1175 E:1179 ||| DT
implementation  ||| S:1179 E:1194 ||| NN
of  ||| S:1194 E:1197 ||| IN
pneumococcal  ||| S:1197 E:1210 ||| JJ
vaccination  ||| S:1210 E:1222 ||| NN
at  ||| S:1222 E:1225 ||| IN
the  ||| S:1225 E:1229 ||| DT
national  ||| S:1229 E:1238 ||| JJ
level ||| S:1238 E:1243 ||| NN
.  ||| S:1243 E:1245 ||| .
A  ||| S:1245 E:1247 ||| DT
total  ||| S:1247 E:1253 ||| NN
of  ||| S:1253 E:1256 ||| IN
257  ||| S:1256 E:1260 ||| CD
isolates  ||| S:1260 E:1269 ||| NN
of  ||| S:1269 E:1272 ||| IN
culture-confirmed  ||| S:1272 E:1290 ||| NNP
Streptococcus  ||| S:1290 E:1304 ||| NNP
pneumoniae  ||| S:1304 E:1315 ||| NN
were  ||| S:1315 E:1320 ||| VBD
evaluated ||| S:1320 E:1329 ||| VBN
.  ||| S:1329 E:1331 ||| .
Considering  ||| S:1331 E:1343 ||| VBG
all  ||| S:1343 E:1347 ||| DT
age  ||| S:1347 E:1351 ||| NN
groups ||| S:1351 E:1357 ||| NNS
,  ||| S:1357 E:1359 ||| ,
vaccine  ||| S:1359 E:1367 ||| NN
coverage  ||| S:1367 E:1376 ||| NN
was  ||| S:1376 E:1380 ||| VBD
41.4 ||| S:1380 E:1384 ||| CD
% ||| S:1384 E:1385 ||| NN
,  ||| S:1385 E:1387 ||| ,
53.9 ||| S:1387 E:1391 ||| CD
% ||| S:1391 E:1392 ||| NN
,  ||| S:1392 E:1394 ||| ,
and  ||| S:1394 E:1398 ||| CC
67.2 ||| S:1398 E:1402 ||| CD
%  ||| S:1402 E:1404 ||| NN
for  ||| S:1404 E:1408 ||| IN
PCV7 ||| S:1408 E:1412 ||| NNP
,  ||| S:1412 E:1414 ||| ,
PCV10 ||| S:1414 E:1419 ||| NNP
,  ||| S:1419 E:1421 ||| ,
and  ||| S:1421 E:1425 ||| CC
PCV13  ||| S:1425 E:1431 ||| CD
serotypes ||| S:1431 E:1440 ||| NN
,  ||| S:1440 E:1442 ||| ,
respectively ||| S:1442 E:1454 ||| RB
;  ||| S:1454 E:1456 ||| :
for  ||| S:1456 E:1460 ||| IN
patients  ||| S:1460 E:1469 ||| NNS
< ||| S:1469 E:1470 ||| SYM
2 ||| S:1470 E:1471 ||| CD
,  ||| S:1471 E:1473 ||| ,
2-5 ||| S:1473 E:1476 ||| CD
,  ||| S:1476 E:1478 ||| ,
and  ||| S:1478 E:1482 ||| CC
> ||| S:1482 E:1483 ||| CD
60  ||| S:1483 E:1486 ||| CD
years  ||| S:1486 E:1492 ||| NNS
of  ||| S:1492 E:1495 ||| IN
age ||| S:1495 E:1498 ||| NN
,  ||| S:1498 E:1500 ||| ,
PCV7  ||| S:1500 E:1505 ||| CD
coverage  ||| S:1505 E:1514 ||| NN
was  ||| S:1514 E:1518 ||| VBD
50 ||| S:1518 E:1520 ||| CD
% ||| S:1520 E:1521 ||| NN
,  ||| S:1521 E:1523 ||| ,
51 ||| S:1523 E:1525 ||| CD
% ||| S:1525 E:1526 ||| NN
,  ||| S:1526 E:1528 ||| ,
and  ||| S:1528 E:1532 ||| CC
35 ||| S:1532 E:1534 ||| CD
% ||| S:1534 E:1535 ||| NN
,  ||| S:1535 E:1537 ||| ,
respectively ||| S:1537 E:1549 ||| RB
;  ||| S:1549 E:1551 ||| :
PCV10  ||| S:1551 E:1557 ||| CD
coverage  ||| S:1557 E:1566 ||| NN
was  ||| S:1566 E:1570 ||| VBD
53 ||| S:1570 E:1572 ||| CD
% ||| S:1572 E:1573 ||| NN
,  ||| S:1573 E:1575 ||| ,
74 ||| S:1575 E:1577 ||| CD
% ||| S:1577 E:1578 ||| NN
,  ||| S:1578 E:1580 ||| ,
45 ||| S:1580 E:1582 ||| CD
% ||| S:1582 E:1583 ||| NN
,  ||| S:1583 E:1585 ||| ,
respectively ||| S:1585 E:1597 ||| RB
;  ||| S:1597 E:1599 ||| :
and  ||| S:1599 E:1603 ||| CC
PCV13  ||| S:1603 E:1609 ||| CD
coverage  ||| S:1609 E:1618 ||| NN
was  ||| S:1618 E:1622 ||| VBD
63 ||| S:1622 E:1624 ||| CD
% ||| S:1624 E:1625 ||| NN
,  ||| S:1625 E:1627 ||| ,
80 ||| S:1627 E:1629 ||| CD
% ||| S:1629 E:1630 ||| NN
,  ||| S:1630 E:1632 ||| ,
and  ||| S:1632 E:1636 ||| CC
68 ||| S:1636 E:1638 ||| CD
% ||| S:1638 E:1639 ||| NN
,  ||| S:1639 E:1641 ||| ,
respectively ||| S:1641 E:1653 ||| RB
.  ||| S:1653 E:1655 ||| .
Overall ||| S:1655 E:1662 ||| RB
,  ||| S:1662 E:1664 ||| ,
17.4 ||| S:1664 E:1668 ||| CD
%  ||| S:1668 E:1670 ||| NN
of  ||| S:1670 E:1673 ||| IN
these  ||| S:1673 E:1679 ||| DT
isolates  ||| S:1679 E:1688 ||| NN
were  ||| S:1688 E:1693 ||| VBD
penicillin-G  ||| S:1693 E:1706 ||| JJ
non-susceptible  ||| S:1706 E:1722 ||| JJ
using  ||| S:1722 E:1728 ||| VBG
the  ||| S:1728 E:1732 ||| DT
latest  ||| S:1732 E:1739 ||| JJS
established  ||| S:1739 E:1751 ||| JJ
breakpoints  ||| S:1751 E:1763 ||| NN
and  ||| S:1763 E:1767 ||| CC
mortality  ||| S:1767 E:1777 ||| NN
occurred  ||| S:1777 E:1786 ||| VBD
in  ||| S:1786 E:1789 ||| IN
23.5 ||| S:1789 E:1793 ||| CD
%  ||| S:1793 E:1795 ||| NN
of  ||| S:1795 E:1798 ||| IN
the  ||| S:1798 E:1802 ||| DT
patients  ||| S:1802 E:1811 ||| NNS
with  ||| S:1811 E:1816 ||| IN
non-susceptible  ||| S:1816 E:1832 ||| JJ
isolates ||| S:1832 E:1840 ||| NN
.  ||| S:1840 E:1842 ||| .
In  ||| S:1842 E:1845 ||| IN
addition ||| S:1845 E:1853 ||| NN
,  ||| S:1853 E:1855 ||| ,
10.9 ||| S:1855 E:1859 ||| CD
%  ||| S:1859 E:1861 ||| NN
of  ||| S:1861 E:1864 ||| IN
isolates  ||| S:1864 E:1873 ||| NN
were  ||| S:1873 E:1878 ||| VBD
multi-drug-resistant ||| S:1878 E:1898 ||| JJ
.  ||| S:1898 E:1900 ||| .
The  ||| S:1900 E:1904 ||| DT
highest  ||| S:1904 E:1912 ||| JJS
mortality  ||| S:1912 E:1922 ||| NN
rates  ||| S:1922 E:1928 ||| NNS
were  ||| S:1928 E:1933 ||| VBD
observed  ||| S:1933 E:1942 ||| VBN
in  ||| S:1942 E:1945 ||| IN
the  ||| S:1945 E:1949 ||| DT
eldest  ||| S:1949 E:1956 ||| NN
( ||| S:1956 E:1957 ||| -LRB-
> ||| S:1957 E:1958 ||| CD
60  ||| S:1958 E:1961 ||| CD
years  ||| S:1961 E:1967 ||| NNS
of  ||| S:1967 E:1970 ||| IN
age ||| S:1970 E:1973 ||| NN
)  ||| S:1973 E:1975 ||| -RRB-
and  ||| S:1975 E:1979 ||| CC
youngest  ||| S:1979 E:1988 ||| JJS
(  ||| S:1988 E:1989 ||| -LRB-
< ||| S:1989 E:1990 ||| SYM
2  ||| S:1990 E:1992 ||| CD
years  ||| S:1992 E:1998 ||| NNS
of  ||| S:1998 E:2001 ||| IN
age ||| S:2001 E:2004 ||| NN
)  ||| S:2004 E:2006 ||| -RRB-
patients ||| S:2006 E:2014 ||| NNS
.  ||| S:2014 E:2016 ||| .
The  ||| S:2016 E:2020 ||| DT
most  ||| S:2020 E:2025 ||| RBS
prevalent  ||| S:2025 E:2035 ||| JJ
invasive  ||| S:2035 E:2044 ||| NNS
serotypes  ||| S:2044 E:2054 ||| VBP
identified  ||| S:2054 E:2065 ||| VBN
were  ||| S:2065 E:2070 ||| VBD
those  ||| S:2070 E:2076 ||| DT
found  ||| S:2076 E:2082 ||| VBN
in  ||| S:2082 E:2085 ||| IN
currently  ||| S:2085 E:2095 ||| RB
available  ||| S:2095 E:2105 ||| JJ
pneumococcal  ||| S:2105 E:2118 ||| JJ
conjugate  ||| S:2118 E:2128 ||| JJ
vaccines ||| S:2128 E:2136 ||| NNS
,  ||| S:2136 E:2138 ||| ,
emphasizing  ||| S:2138 E:2150 ||| VBG
the  ||| S:2150 E:2154 ||| DT
importance  ||| S:2154 E:2165 ||| NN
of  ||| S:2165 E:2168 ||| IN
implementing  ||| S:2168 E:2181 ||| VBG
the  ||| S:2181 E:2185 ||| DT
vaccine  ||| S:2185 E:2193 ||| NN
in  ||| S:2193 E:2196 ||| IN
the  ||| S:2196 E:2200 ||| DT
routine  ||| S:2200 E:2208 ||| JJ
immunization  ||| S:2208 E:2221 ||| JJ
schedule  ||| S:2221 E:2230 ||| NN
at  ||| S:2230 E:2233 ||| IN
the  ||| S:2233 E:2237 ||| DT
national  ||| S:2237 E:2246 ||| JJ
level ||| S:2246 E:2251 ||| NN
.  ||| S:2251 E:2253 ||| .
Continuation  ||| S:2253 E:2266 ||| NN
of  ||| S:2266 E:2269 ||| IN
current  ||| S:2269 E:2277 ||| JJ
surveillance  ||| S:2277 E:2290 ||| NN
practices  ||| S:2290 E:2300 ||| NNS
will  ||| S:2300 E:2305 ||| MD
help  ||| S:2305 E:2310 ||| VB
assess  ||| S:2310 E:2317 ||| VB
the  ||| S:2317 E:2321 ||| DT
impact  ||| S:2321 E:2328 ||| NN
of  ||| S:2328 E:2331 ||| IN
vaccine  ||| S:2331 E:2339 ||| NN
implementation  ||| S:2339 E:2354 ||| NN
on  ||| S:2354 E:2357 ||| IN
IPD  ||| S:2357 E:2361 ||| NNP
epidemiology ||| S:2361 E:2373 ||| NN
,  ||| S:2373 E:2375 ||| ,
serotype  ||| S:2375 E:2384 ||| JJ
distribution  ||| S:2384 E:2397 ||| NN
and  ||| S:2397 E:2401 ||| CC
antibiotic  ||| S:2401 E:2412 ||| JJ
resistance  ||| S:2412 E:2423 ||| NN
patterns ||| S:2423 E:2431 ||| NNS
.  ||| S:2431 E:2433 ||| .
